Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial.

ABSTRACT:

Aim

This study aimed to investigate the efficacy and safety of bi-weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase-4 inhibitors (DPP-4is) in Chinese patients with type 2 diabetes mellitus (T2DM).

Methods

This multicenter, open-label, randomized controlled study assigned participants in a 1:1 ratio to either the daily DPP-4i group or the 10 mg cofrogliptin group. The DPP-4i group continued their original daily DPP-4i regimen for 24 weeks, whereas the cofrogliptin group discontinued the daily DPP-4i and received the investigational drug orally once every 2 weeks. All participants underwent 14-day continuous glucose monitoring at weeks 10-12 and 22-24 during the treatment period. The main endpoint was the change in glucose time in range (TIR; 3.9-10

SUBMITTER: Pan C 

PROVIDER: S-EPMC12803542 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature